New drug combo shows promise for rare thyroid cancer in early trial

NCT ID NCT06902376

First seen Nov 05, 2025 · Last updated May 14, 2026 · Updated 23 times

Summary

This early-phase study tests whether giving two drugs (XL092 and cemiplimab) before surgery can help remove a rare and fast-growing thyroid cancer called anaplastic thyroid cancer. The study includes 12 adults whose cancer has a specific gene change (BRAF V600E). The main goals are to see if the treatment is safe and if it makes the tumor easier to fully remove during surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana Farber/Harvard Cancer Center

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-••••

  • University of North Carolina at Chapel Hill

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.